A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin

Clinical Therapeutics

Volumn 30, Issue 1, 2008, Pages 121-130

  Piazuelo, Elena ^a,b   Fuentes, Javier ^c   Garcfa González, María Asunción ^a,b   Jiménez, Pilar ^a,b   Lanas, Angel ^a,b,d  

^a INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Aspirin.; Endothelial nitric oxide synthase; Gastrointestinal bleeding; Glycoprotein IIb IIIa receptor; Polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; NITRATE; STOMACH SECRETION INHIBITOR; VASODILATOR AGENT;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BASE PAIRING; CASE CONTROL STUDY; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFECT; ENOS GENE; FEMALE; GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GPIIIA GENE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOGISTIC REGRESSION ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PROTECTION; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SPAIN; UPPER GASTROINTESTINAL BLEEDING; VARIABLE NUMBER OF TANDEM REPEAT;

AGED; ALCOHOL DRINKING; ASPIRIN; CASE-CONTROL STUDIES; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HELICOBACTER INFECTIONS; HUMANS; INTEGRIN BETA3; INTRONS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PEPTIC ULCER; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; RISK FACTORS; VASODILATOR AGENTS;

EID: 45249104350     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.020     Document Type: Article

References (50)

1. Stalnikowicz-Darvasi R. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis. J Clin Gastroenterol 21 (1995) 13-16
2. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
3. Lanas A., Bajador E., Serrano P., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343 (2000) 834-839
4. Serrano P., Lanas A., Arroyo M., and Ferreira I. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 16 (2002) 1945-1953
5. Lanas A., Fuentes J., Benito R., et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 16 (2002) 779-786
6. Chan F., Chung S., Suen B., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
7. Martínez C., Blanco G., Ladero J., et al. Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. Br J Pharmacol 141 (2004) 205-208
8. Day J., Lanas A., Rustagi P., and Hirschowitz B. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. J Clin Gastroenterol 22 (1996) 96-103
9. Lanas A., Arroyo M., Esteva F., et al. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut. 39 (1996) 654-660
10. Plow E., and Byzova T. The biology of glycoprotein IIb-IIIa. Coron Artery Dis 10 (1999) 547-551
11. Phillips D., Charo I., and Scarborough R. GPIIb-IIIa: The responsive integrin. Cell 65 (1991) 359-362
12. Newman P., Derbes R., and Aster R. The human platelet al-loantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 83 (1989) 1778-1781
13. Cooke G., Bray P., Hamlington J., et al. PlA2 polymorphism and efficacy of aspirin. Lancet 351 (1998) 1253
14. Michelson A., Furman M., Goldschmidt-Clermont P., et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101 (2000) 1013-1018
15. Macchi L., Christiaens L., Brabant S., et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 42 (2003) 1115-1119
16. Undas A., Sanak M., Musial J., and Szczeklik A. Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 353 (1999) 982-983
17. Szczeklik A., Undas A., Sanak M., et al. Relationship between bleeding time, aspirin and the PIA1/A2 polymorphism of platelet glycoprotein IlIa. Br J Haematol 110 (2000) 965-967
18. Cooke G., Liu-Stratton Y., Ferketich A., et al. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination. J Am Coll Cardiol 47 (2006) 541-546
19. Feng D., Lindpaintner K., Larson M., et al. Increased platelet aggregability associated with platelet G PIIIa PIA2 polymorphism: The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 19 (1999) 1142-1147
20. Vijayan K., Goldschmidt-Clermont P., Roos C., and Bray P. The PI(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. J Clin Invest 105 (2000) 793-802
21. Andrioli G., Minuz P., Solero P., et al. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with PI(A2) polymorphism of beta(3) subunit (glycoprotein IlIa). Br J Haematol 110 (2000) 911-918
22. Furlong B., Henderson A., Lewis M., and Smith J. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 90 (1987) 687-692
23. Radomski M., Palmer R., and Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 92 (1987) 639-646
24. Bhardwaj R., Page C., May G., and Moore P. Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Eur J Pharmacol 157 (1988) 83-91
25. Golino P., Cappelli-Bigazzi M., Ambrosio G., et al. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ Res 71 (1992) 1447-1456
26. Bodzenta-Lukaszyk A., Gabryelewicz A., Lukaszyk A., et al. Nitric oxide synthase inhibition and platelet function. Thromb Res 75 (1994) 667-672
27. Simon D., Stamler J., Loh E., et al. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 26 (1995) 339-342
28. Sessa W., Harrison J., Barber C., et al. Molecular cloning and expression of a cDNA encoding endothelial cell nitric oxide synthase. J Biol Chem 267 (1992) 15274-15276
29. Sase K., and Michel T. Expression of constitutive endothelial nitric oxide synthase in human blood platelets. Life Sci 57 (1995) 2049-2055
30. Wang X., Mahaney M., Sim A., et al. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arterioscler Thromb Vasc Biol 17 (1997) 3147-3153
31. Serrano T., Piazuelo E., Benito R., et al. Bleeding duodenal ulcer and association with polymorphism of endothelial constitutive nitric oxide synthase gene. Dig Dis Sci 47 (2002) 996-1000
32. Everhart J. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 29 (2000) 559-578
33. Bernersen B., Johnsen R., Straume B., et al. Towards a true prevalence of peptic ulcer: The Sørreisa gastrointestinal disorder study. Gut 31 (1990) 989-992
34. Weiss E., Bray P., Tayback M., et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334 (1996) 1090-1094
35. Carter A., Ossei-Gerning N., Wilson I., and Grant P. Association of the platelet PI(A) polymorphism of glycoprotein llb/llla and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease. Circulation 96 (1997) 1424-1431
36. Burr D., Doss H., Cooke G., and Goldschmidt-Clermont P. A meta-analysis of studies on the association of the platelet PIA polymorphism of glycoprotein IlIa and risk of coronary heart disease. Stat Med 22 (2003) 1741-1760
37. Streifler J., Rosenberg N., Chetrit A., et al. Cerebrovascular events in patients with significant stenosis of the carotid artery are associated with hyperho-mocysteinemia and platelet antigen-1 (Leu33Pro) polymorphism. Stroke 32 (2001) 2753-2758
38. Kunnas T., llveskoski E., Niskakangas T., et al. Association of the endothelial nitric oxide synthase gene polymorphism with risk of coronary artery disease and myocardial infarction in middle-aged men. J Mol Med 80 (2002) 605-609
39. Wang X., Sim A., Badenhop R., et al. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 2 (1996) 41-45
40. Blin N., and Stafford D. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3 (1976) 2303-2308
41. Unkelbach K., Kalb R., Santoso S., et al. Genomic RFLP typing of human platelet alloantigens Zw(PIA), Ko, Bak and Br (HPA-1, 2, 3, 5). Br J Haematol 89 (1995) 169-176
42. Lasne D., Krenn M., Pingault V., et al. Interdonor variability of platelet response to thrombin receptor activation: Influence of PIA2 polymorphism. Br J Haematol 99 (1997) 801-807
43. Salido E., Martín B., Barrios Y., et al. The PIA2 polymorphism of the platelet glycoprotein MIA gene as a risk factor for acute renal allograft rejection. J Am Soc Nephrol 10 (1999) 2599-2605
44. Tsukada T., Yokoyama K., Arai T., et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 245 (1998) 190-193
45. Wallace J., and Miller M. Nitric oxide in mucosal defense: A little goes a long way. Gastroenterology 119 (2000) 512-520
46. Song J., Yoon Y., Park K., et al. Genotype-specific influence on nitric oxide synthase gene expression, protein concentrations, and enzyme activity in cultured human endothelial cells. Clin Chem 49 (2003) 847-852
47. Jeerooburkhan N., Jones L., Bujac S., et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 38 (2001) 1054-1061
48. Lanas A., Bajador E., Serrano P., et al. Effects of nitrate and prophylactic aspirin on upper gastrointestinal bleeding: A retrospective case-control study. J Int Med Res 26 (1998) 120-128
49. Asakimori Y., Yorioka N., Taniguchi Y., et al. T(-786)->C polymorphism of the endothelial nitric oxide synthase gene influences the progression of renal disease. Nephron 91 (2002) 747-751
50. Gruchala M., Ciecwierz D., Ochman K., et al. Association between the Pl(A) platelet glycoprotein GPIIIa polymorphism and extent of coronary artery disease. Int J Cardiol 88 (2003) 229-237